FSA
TEVA icon

Financial Sense Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Financial Sense Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Hold
0
– -$714K – 118
2023
Q3 		– Hold
0
– – – 68
2023
Q2 		– Hold
0
– – – 67
2022
Q3 		– Hold
0
– -$526K – 97
2022
Q2 		– Hold
0
– – – 71

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Financial Sense Advisors's TEVA Position: Q1 2026 in Review

Financial Sense Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 78% in Q1 2026, selling an estimated $18.9M and leaving 165,236 shares worth $4.98M. The position accounts for 1.01% of the portfolio, ranked #32.

Financial Sense Advisors first reported a position in TEVA in Q2 2017 and has held it in 34 quarters since. The position peaked at $23.5M in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Financial Sense Advisors held 165,236 shares of Teva Pharmaceuticals worth $4.98M as of Q1 2026.
  • Financial Sense Advisors sold 586,347 Teva Pharmaceuticals shares in Q1 2026, an estimated $18.9M.
  • Teva Pharmaceuticals made up 1.01% of Financial Sense Advisors's portfolio in Q1 2026, its #32 holding.
  • Financial Sense Advisors first reported a position in Teva Pharmaceuticals in Q2 2017 and has held it in 34 quarters since.
  • Financial Sense Advisors's Teva Pharmaceuticals position peaked at $23.5M in Q4 2025.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Financial Sense Advisors's 13F filing for Q1 2026, filed 14 May 2026.